-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$7.50-37.34% Downside
Bioventus Inc. Frequently Asked Questions
-
What analysts cover Bioventus Inc.?
Bioventus Inc. has been rated by research analysts at Craig-Hallum, Canaccord Genuity, Goldman Sachs in the past 90 days.